The early clinical data is promising but from a small sample; the stock may rally on the positive readout. Traders should watch for the full EULAR presentation in June for more definitive efficacy and safety data. No financial guidance was provided.
Price Chart
Executive Summary
Cullinan Therapeutics announced initial Phase 1 clinical data for CLN-978 in RA and SLE, showing robust B cell depletion and early efficacy signals with a favorable safety profile. The data will be presented at EULAR in June 2026. While positive, the dataset is limited to 14 patients and very early stage.
Key Facts
- 14 patients dosed across RA (n=5) and SLE (n=9) trials as of January 14, 2026 cutoff
- 9 out of 11 patients exhibited >75% B cell depletion after 10 mcg dosing
- 4 out of 5 RA patients had decreases in DAS28-ESR, including 3 to moderate activity and 1 to remission
- 5 out of 6 SLE patients had a decrease in SLEDAI score of >4 points
- CLN-978 is a subcutaneously administered CD19xCD3 T cell engager developed internally
- Updated data, including additional patients, to be presented at EULAR in June 2026
Financial Impact
No direct financial impact; clinical data update for pre-revenue stage firm
Risk Factors
- Interim data from only 14 patients; final results may differ materially
- Safety profile may change with larger patient exposure and longer follow-up
- Competitive landscape in CD19-targeted autoimmunity (e.g., from Kyverna, Cabaletta)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-229173 |
| Document: cgem-ex99_1.htm | 0001193125-26-229173 |
| Document: 0001193125-26-229173-index-headers.html | 0001193125-26-229173 |
| Document: 0001193125-26-229173-index.html | 0001193125-26-229173 |
| Document: 0001193125-26-229173.txt | 0001193125-26-229173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $15.51 | awaiting T+60 | — | $14.54 (−6.25%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.54 (−32.90%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.54 (−28.73%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.54 (−19.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.54 (+12.02%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.54 (+20.66%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.54 (+9.49%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.54 (+2.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers